If you’re searching for information about bone marrow transplantation in a Spanish context, you likely want to know how the procedure works within Spain’s healthcare system, which centers perform it, how donor registries operate in Spanish-speaking countries, or how to navigate this process as a Spanish-speaking patient. This guide covers all of that — with real data, specific centers, and practical advice.
Spain is one of Europe’s leaders in transplant medicine. The Organización Nacional de Trasplantes (ONT) has coordinated organ and tissue donation since 1989, and Spain consistently ranks at or near the top globally in donation rates. In 2022, Spanish centers performed over 3,500 hematopoietic stem cell transplants, according to data from the European Society for Blood and Marrow Transplantation (EBMT). The procedure — known as trasplante de médula ósea or trasplante de progenitores hematopoyéticos (TPH) — is fully covered under Spain’s public healthcare system.
What Is Bone Marrow Transplantation?
A bone marrow transplant replaces damaged or diseased hematopoietic stem cells — the cells in your bone marrow responsible for producing red blood cells, white blood cells, and platelets — with healthy ones. When bone marrow fails due to cancer, genetic disease, or treatment toxicity, transplantation can be the only curative option.
The procedure itself involves infusing stem cells intravenously, much like a blood transfusion, after the patient undergoes a conditioning regimen of chemotherapy and/or radiation to destroy the diseased marrow and suppress the immune system enough to accept new cells.
Types of Transplants Performed in Spain
| Type | Spanish Term | Stem Cell Source | Key Indication | Approximate % in Spain |
|---|---|---|---|---|
| Autologous | Trasplante autólogo | Patient’s own cells | Multiple myeloma, lymphoma | ~55–60% |
| Allogeneic (matched related) | Trasplante alogénico emparentado | HLA-matched sibling | Acute leukemia, aplastic anemia | ~15–20% |
| Allogeneic (unrelated donor) | Trasplante alogénico no emparentado | Registry donor | Acute leukemia, MDS | ~15% |
| Haploidentical | Trasplante haploidéntico | Half-matched family member | When no matched donor exists | ~10% (growing rapidly) |
Haploidentical transplants have surged in Spain over the past decade. Advances in post-transplant cyclophosphamide protocols mean that a parent, child, or half-matched sibling can now serve as a donor — dramatically expanding the donor pool, which is especially significant for patients from underrepresented ethnic backgrounds who struggle to find matched unrelated donors.
Spain’s Donor Registry: REDMO
The Registro Español de Donantes de Médula Ósea (REDMO), managed by the Fundación Josep Carreras, is Spain’s national bone marrow donor registry. As of 2023, REDMO has surpassed 450,000 registered donors, and it connects to the worldwide registry network of over 40 million donors through the World Marrow Donor Association (WMDA).
Registering as a donor in Spain is straightforward: you need to be between 18 and 40 years old, weigh at least 50 kg, and be in good general health. Registration involves a simple saliva swab or blood sample at participating hospitals or blood banks. The actual donation — if called — involves either peripheral blood stem cell collection (80% of cases, using apheresis after 4–5 days of G-CSF injections) or a surgical bone marrow harvest under general anesthesia.
Leading Transplant Centers in Spain
- Hospital Clínic de Barcelona — One of the highest-volume allogeneic transplant programs in Europe, with pioneering work in CAR-T therapy
- Hospital Universitario La Paz (Madrid) — Major pediatric and adult transplant center
- Hospital de la Santa Creu i Sant Pau (Barcelona) — Long-standing expertise in MDS and leukemia transplants
- Hospital Universitario de Salamanca — A national reference center for multiple myeloma
- Hospital Universitario Virgen del Rocío (Seville) — Leading center in southern Spain
Spain’s JACIE-accredited centers (Joint Accreditation Committee of ISCT and EBMT) meet the same quality standards as top programs in Germany, France, and the United States.
Conditions Treated with BMT in Spanish-Speaking Populations
The indications for transplant are the same globally, but disease prevalence varies. In Spain and Latin America, certain conditions carry particular relevance:
- Acute lymphoblastic leukemia (ALL) — More common in Hispanic/Latino pediatric populations
- Sickle cell disease — Increasingly treated with curative allogeneic transplant; relevant in Afro-Latino communities
- Aplastic anemia — Severe cases in young patients are often cured with matched sibling transplant (survival >90%)
- Multiple myeloma — The most common indication for autologous transplant worldwide; Spain has contributed key clinical trial data through the GEM/PETHEMA group
Survival Rates and Outcomes
Outcomes depend heavily on disease type, stage, donor match quality, and patient age. Here are general benchmarks from EBMT and CIBMTR data:
- Autologous transplant for myeloma: ~95% survive the transplant itself; median progression-free survival is 3–5 years
- Allogeneic transplant for acute leukemia (first remission): 55–70% overall survival at 5 years
- Matched sibling transplant for severe aplastic anemia (age <40): >90% long-term survival
- Haploidentical transplants: Outcomes now approaching matched unrelated donor results, with 50–65% overall survival depending on diagnosis
Transplant-related mortality has decreased significantly over the past two decades thanks to better conditioning regimens, infection prophylaxis, and graft-versus-host disease (GVHD) prevention strategies.
Language and Cultural Considerations for Spanish-Speaking Patients
Navigating a bone marrow transplant is stressful enough without language barriers. Spanish-speaking patients in the U.S. face documented disparities in transplant access — a 2021 study in Blood Advances found that Hispanic patients were 30–40% less likely to receive an allogeneic transplant compared to non-Hispanic white patients, even after controlling for disease and insurance status.
Practical steps to bridge this gap:
- Request a certified medical interpreter — not a family member — for consent discussions and treatment planning
- Ask for written materials in Spanish (consentimiento informado, discharge instructions, medication guides)
- Contact the Fundación Josep Carreras (Spain) or Be The Match (U.S., with Spanish-language resources) for patient support
- Register with REDMO or Be The Match to increase donor diversity — Hispanic/Latino patients have only a ~46% chance of finding a fully matched unrelated donor, compared to ~75% for white patients of European descent
Frequently Asked Questions
How do I say “bone marrow transplant” in Spanish?
The standard term is trasplante de médula ósea. In clinical settings, you’ll also hear trasplante de progenitores hematopoyéticos (TPH), which more accurately reflects that stem cells — not marrow tissue itself — are being transplanted. Both terms are widely understood across all Spanish-speaking countries.
Is bone marrow transplant free in Spain?
Yes. Under Spain’s Sistema Nacional de Salud (SNS), bone marrow transplantation is fully covered for all residents. This includes conditioning chemotherapy, the transplant itself, hospitalization, and post-transplant follow-up. Non-residents may face different rules depending on bilateral healthcare agreements.
How long is the hospital stay for a transplant in Spain?
For autologous transplants, expect 2–3 weeks of inpatient stay. Allogeneic transplants typically require 4–6 weeks, sometimes longer if complications like GVHD or infections arise. After discharge, patients need close outpatient follow-up for at least 3–6 months.
Can I donate bone marrow if I live in Latin America?
Many Latin American countries have national registries connected to the WMDA network: Argentina (INCUCAI), Brazil (REDOME — the world’s third-largest registry with over 5 million donors), Mexico (DONARE), and Chile (registry through the Ministerio de Salud). Registration requirements are similar to Spain’s.
What is the biggest risk of bone marrow transplantation?
For allogeneic transplants, graft-versus-host disease (GVHD) — called enfermedad injerto contra huésped (EICH) in Spanish — is the most significant complication. It occurs when donor immune cells attack the recipient’s tissues. Acute GVHD affects 30–50% of patients, and chronic GVHD can persist for years. Modern prophylaxis has reduced severe forms considerably.
Key Takeaways
- Spain performs over 3,500 stem cell transplants annually and is a European leader in transplant medicine
- The procedure is fully covered under Spain’s public health system
- REDMO and international registries give Spanish-speaking patients access to a global donor pool of 40+ million
- Hispanic/Latino patients face donor matching challenges — increasing registry diversity is critical
- Haploidentical transplant has expanded donor options dramatically, especially for minority populations
- If you’re a Spanish-speaking patient in the U.S., always request a professional interpreter and Spanish-language written materials — this is your right
